DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Biosimilars | Emerging Biosimilars | Truxima Launch Tracker | Germany | Wave 1 | 2017
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Non-Small-Cell Lung Cancer | Access and Reimbursement | Brazil and Mexico | 2017
Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…
Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription…
Acute Coronary Syndrome | Access and Reimbursement | Accountable Care Organizations | US | 2017
Introduction: This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers’ and…